U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07141186) titled 'QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy' on July 23.
Brief Summary: To explore the efficacy and safety of administrating QL1706 in patients with recurrent and/or metastatic cervical cancer who had developed resistance to prior PD-1/PD-L1 antibody therapies.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Cervical Cancer
Cervical Cancer Metastatic
Cervical Cancer Recurrent
Cervical Adenocarcinoma
Cervical Cancer Squamous Cell
Intervention:
DRUG: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Enrolled patients will receive intravenou...